GLP-1 Medications and Asthma: What the Research Shows

Introduction

The connection between GLP-1 medications and asthma was not something anyone set out to find. Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were designed to lower blood sugar and body weight — yet as millions of people with obesity started taking them, their pulmonologists noticed something unexpected: their asthma was getting quieter. Fewer flare-ups, fewer steroid courses, fewer trips to the emergency department.

Asthma affects roughly 25 million Americans, and a large share of them carry excess weight that makes the disease harder to control. Obesity-related asthma is its own beast — more severe, more steroid-resistant, and poorly explained by the classic allergic mechanisms that standard inhalers target. So when a drug class that strips away visceral fat also appears to calm the airways, the question stops being a curiosity and becomes a serious clinical signal worth examining.

This is what the research actually shows about GLP-1 medications and asthma — who benefits, by how much, and where the evidence still has gaps.

Why Obesity Makes Asthma Worse

Asthma in people with obesity is not simply ordinary asthma in a heavier body. It is a distinct clinical phenotype, and understanding why explains where GLP-1 drugs fit.

Excess weight worsens airway disease through several overlapping routes. Mechanically, abdominal and chest-wall fat restrict lung expansion and reduce the volume the lungs operate at, leaving the airways narrower and more prone to closing. Metabolically, adipose tissue is not inert storage — it is an active endocrine organ that pumps out inflammatory signals. In obesity, this drives a low-grade, body-wide inflammation that spills into the lungs and produces a type of airway inflammation that responds poorly to inhaled corticosteroids, the cornerstone of conventional asthma care.

Evidence: "Obesity-related asthma represents a distinct phenotype characterized by greater severity, reduced response to corticosteroids, and a predominantly non-type 2 inflammatory profile driven by metabolic dysregulation rather than allergic mechanisms." — Menzella F, et al. Journal of International Medical Research. 2025. DOI: 10.1177/03000605251392717

This is the crux. The patients whose asthma is hardest to treat are frequently the same patients carrying the most metabolic risk — and the inflammation behind their wheezing is the kind standard inhalers were never built to silence. A treatment that addressed the metabolic driver, rather than just dilating the airway after the fact, would be filling a real gap. That overlap is also why the link between GLP-1 drugs and sleep apnea — another obesity-driven respiratory problem — has drawn similar attention.

What the Cohort Studies Show in Adults

The first hard signal came from diabetes data. Researchers had access to large patient records where some people with type 2 diabetes and asthma had been started on a GLP-1 receptor agonist while others received different glucose-lowering drugs — a natural comparison.

Evidence: "Adults with asthma and type 2 diabetes had lower counts of asthma exacerbations and reduced asthma symptoms after initiating a glucagon-like peptide-1 receptor agonist compared with other agents for diabetes treatment intensification." — Foer D, et al. American Journal of Respiratory and Critical Care Medicine. 2021. DOI: 10.1164/rccm.202004-0993OC

A second large cohort widened the lens from asthma to chronic lower respiratory disease as a whole, and found the protective association held — and was sizable.

Evidence: "GLP-1 receptor agonist use was associated with a hazard ratio of 0.52 for time to first chronic lower respiratory disease inpatient encounter and an incidence rate ratio of 0.70 for the count of exacerbations, relative to DPP-4 inhibitors." — Albogami Y, et al. Diabetes Care. 2021. DOI: 10.2337/dc20-1794

As more of these analyses accumulated, a 2025 systematic review pooled them to ask whether the pattern was consistent across studies rather than a fluke of any single dataset.

Evidence: "Across six retrospective observational studies totaling 62,678 patients, GLP-1 receptor agonist use was associated with a significantly lower risk of asthma and COPD exacerbations compared with sulfonylureas or DPP-4 inhibitors." — Foer D, et al. Respiratory Medicine. 2025. PII: S0954-6111(25)00259-8

The pooled picture is consistent in direction even if the magnitude varies by comparison group. Here is how the major adult findings line up:

Study / population	Comparison	Key result
Foer 2021 (adults, T2D + asthma)	GLP-1 RA vs other diabetes drugs	Fewer exacerbations and symptoms
Albogami 2021 (adults, T2D + CLRD)	GLP-1 RA vs DPP-4 inhibitor	HR 0.52 for hospitalization; IRR 0.70 for exacerbations
Systematic review 2025 (62,678 adults)	GLP-1 RA vs sulfonylurea / DPP-4i	Significantly lower exacerbation risk

One important nuance from the pooled data: the benefit was clear against sulfonylureas and DPP-4 inhibitors but not statistically distinguishable from SGLT2 inhibitors — a hint that part of the effect may travel with metabolic improvement broadly rather than being unique to the GLP-1 pathway alone.

What the Cohort Studies Show in Adolescents

The most striking recent data moved beyond diabetes into the population where the obesity–asthma overlap is most consequential: teenagers. A 2025 propensity-matched cohort study in JAMA Network Open tracked adolescents with overweight or obesity and asthma, comparing those started on a GLP-1 receptor agonist with closely matched peers who were not.

Evidence: "Among 1,070 matched adolescents, acute asthma exacerbations occurred in 5.4% of GLP-1 receptor agonist users versus 10.7% of controls over 12 months (relative risk, 0.51), with fewer emergency department visits and systemic corticosteroid prescriptions." — Huang YC, et al. JAMA Network Open. 2025. DOI: 10.1001/jamanetworkopen.2025.51611

The numbers are worth sitting with. Exacerbations were cut roughly in half. Emergency department visits fell from 3.6% to 1.5% (relative risk 0.42), and systemic steroid prescriptions — the marker every asthma specialist wants to minimize because of their long-term harms in growing patients — dropped from 31.4% to 20.7%. For adolescents, whose asthma trajectory and steroid exposure shape decades of lung and bone health, a roughly one-third reduction in steroid courses is not a minor convenience.

What makes the adolescent data particularly informative is that these patients overwhelmingly did not have diabetes. That weakens the alternative explanation that better glucose control, rather than the drug itself, was doing the work — and points toward weight loss and the airway effects of GLP-1 signaling as the more likely mechanisms.

How GLP-1 Drugs Act on the Asthmatic Airway

Why would a metabolic drug touch the lungs at all? The answer runs along three threads, and they are not mutually exclusive.

Weight loss relieves the mechanical and metabolic load. Shedding visceral fat restores lung volumes and removes a major source of the systemic inflammation that fuels obesity-related asthma. This alone would predict fewer attacks, since weight reduction has long been one of the few non-drug interventions that genuinely improves asthma control.

GLP-1 receptors exist in the airway itself. This is the more provocative finding. GLP-1 receptors are expressed on lung tissue, including airway smooth muscle and immune cells, which means the drugs may act directly rather than only through the scale.

Evidence: "GLP-1 receptor agonists exert direct anti-inflammatory effects in the airway, reducing both type 2 and non-type 2 inflammation, airway smooth muscle reactivity, and mucus production independent of weight loss." — Menzella F, et al. Journal of International Medical Research. 2025. DOI: 10.1177/03000605251392717

The anti-inflammatory effect is systemic. GLP-1 therapy lowers C-reactive protein and other inflammatory markers throughout the body, an effect explored in our review of GLP-1 medications and inflammation. Because obesity-related asthma is fundamentally an inflammatory disease that conventional inhalers struggle to reach, dampening that systemic inflammation may be exactly what calms the steroid-resistant component.

The likely truth is that all three operate together: less fat, a directly quieter airway, and lower body-wide inflammation reinforcing one another. The relative contribution of each is precisely what controlled trials now need to untangle.

The Limits of the Evidence — and What Comes Next

The case for GLP-1 medications in asthma is genuinely promising, but it rests almost entirely on observational data, and that demands restraint.

These are associations, not proof of cause. Cohort studies, however large, cannot fully rule out that people prescribed GLP-1 drugs differ in ways that independently improve their asthma — they may be more engaged with their care, lose weight through other means, or differ in disease severity. A replication analysis across a research network confirmed the respiratory association was reproducible, which strengthens confidence, but reproducibility of an association is not the same as establishing causation.

Evidence: "The protective association between GLP-1 receptor agonists and chronic lower respiratory disease outcomes was replicable across multiple databases, though residual confounding inherent to observational designs could not be excluded." — Conover MM, et al. Pharmacoepidemiology and Drug Safety. 2025. DOI: 10.1002/pds.70087

Drug-to-drug differences remain unsettled. Some analyses suggest the agents are not interchangeable for respiratory outcomes, and head-to-head respiratory comparisons of semaglutide and tirzepatide are still preliminary. The broader trade-offs between the two agents are covered in our tirzepatide vs semaglutide comparison, but for asthma specifically the data is not yet mature enough to crown a winner.

The randomized trial is still running. The decisive test is a placebo-controlled trial that randomizes patients to semaglutide or placebo and measures asthma control directly. The GATA-3 trial (NCT05254314) is doing exactly this in adults with obesity-related symptomatic asthma, and its results will determine whether the observational signal holds up under the most rigorous design. Until then, no GLP-1 drug is approved or recommended as an asthma treatment.

The honest position is this: a person with both obesity and difficult asthma who is otherwise a candidate for a GLP-1 medication may reasonably expect their breathing to improve as a welcome side benefit of weight loss. But choosing one of these drugs specifically to treat asthma is not yet supported — that decision has to wait for the trial data.

Key Takeaways

Multiple large cohort studies link GLP-1 receptor agonists to fewer asthma exacerbations, hospitalizations, and steroid courses, especially in people with obesity-related asthma.
In adults with type 2 diabetes, GLP-1 use was tied to a hazard ratio near 0.52 for respiratory hospitalization; a 2025 systematic review of 62,678 patients confirmed a consistent reduction in exacerbation risk.
A 2025 JAMA Network Open study of adolescents found GLP-1 use roughly halved asthma exacerbations (5.4% vs 10.7%) and cut steroid prescriptions by about a third — in patients who mostly did not have diabetes.
The likely mechanisms are threefold: weight loss easing the metabolic and mechanical burden, direct anti-inflammatory effects via GLP-1 receptors in the airway, and lower systemic inflammation.
The evidence is observational, not causal. The randomized GATA-3 trial of semaglutide in obesity-related asthma will provide the decisive answer.
No GLP-1 medication is currently approved to treat asthma; any respiratory benefit today is a bonus of weight management, not a prescribed indication.

References

Foer D, Beeler PE, Cui J, et al. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists. American Journal of Respiratory and Critical Care Medicine. 2021;203(7):831-840. DOI: 10.1164/rccm.202004-0993OC
Albogami Y, Cusi K, Daniels MJ, et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care. 2021;44(6):1344-1352. DOI: 10.2337/dc20-1794
Huang YC, Tsai MC, Lin TCC, et al. Glucagonlike Peptide-1 Receptor Agonists and Asthma Risk in Adolescents With Obesity. JAMA Network Open. 2025;8(12):e2551611. DOI: 10.1001/jamanetworkopen.2025.51611
Menzella F, Cottini M, Chan R, et al. Unraveling the obesity–asthma link: A new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease. Journal of International Medical Research. 2025;53(11). DOI: 10.1177/03000605251392717
Conover MM, Rao GA, Stürmer T, et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network. Pharmacoepidemiology and Drug Safety. 2025;34(1):e70087. DOI: 10.1002/pds.70087

Last updated: 2026-06-15 Medical review: Dr. James Chen, MD, PhD, FACE